Literature DB >> 10868955

Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression.

L B Maggi1, H Sadeghi, C Weigand, A L Scarim, M R Heitmeier, J A Corbett.   

Abstract

In this study, the anti-inflammatory actions of the peroxisome proliferator-activated receptor (PPAR)-gamma agonists 15-deoxy-delta 12,14-prostaglandin J2 (15-d-delta 12,14-PGJ2) and troglitazone have been examined. Treatment of RAW 264.7 cells and CD-1 mouse peritoneal macrophages with lipopolysaccharide (LPS) + interferon-gamma (IFN-gamma) results in inducible nitric oxide synthase (iNOS), inducible cyclooxygenase (COX-2) and interleukin-1 (IL-1) expression, increased production of nitric oxide, and the release of IL-1. In a concentration-dependent manner, 15-d-delta 12,14-PGJ2 inhibits each of these proinflammatory actions of LPS + IFN-gamma, with half-maximal inhibition at approximately 0.5 microg/ml and complete inhibition at 1-5 microg/ml. The inhibitory actions of 15-d-delta 12,14-PGJ2 on LPS + IFN-gamma-induced inflammatory events are not associated with the inhibition of iNOS enzymatic activity or macrophage cell death, but appear to result from an inhibition of iNOS and IL-1 transcription. In addition, the anti-inflammatory actions of 15-d-delta 12,14-PGJ2 are not limited to peritoneal macrophages, as 15-d-delta 12,14-PGJ2 prevents TNF-alpha + LPS-induced resident islet macrophage expression of IL-1beta and beta-cell expression of iNOS stimulated by the local release of IL-1 in rat islets. 15-d-delta 12,14-PGJ2 appears to be approximately 10-fold more effective at inhibiting resident islet macrophage activation (in response to TNF + LPS) than IL-1-induced nitrite production by beta-cells. Two mechanisms appear to be associated with the antiinflammatory actions of both 15-d-delta 12,14-PGJ2 and troglitazone: 1) the direct inhibition of cytokine- and endotoxin-stimulated iNOS and IL-1 transcription; and 2) the inhibition of IL-1 signaling, an event associated with PPAR-gamma agonist-induced activation of the heat shock response (as assayed by heat shock protein 70 expression). These findings indicate that the PPAR-gamma agonists, troglitazone and the J series of prostaglandins, are potent anti-inflammatory agents that prevent cytokine- and endotoxin-stimulated activation of peripheral and resident tissue macrophages and cytokine-induced iNOS expression by beta-cells by the inhibition of transcriptional activation and induction of the heat shock response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868955     DOI: 10.2337/diabetes.49.3.346

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  24 in total

1.  The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus.

Authors:  D Gupta; T Kono; C Evans-Molina
Journal:  Diabetes Obes Metab       Date:  2010-12       Impact factor: 6.577

Review 2.  PPAR-γ -- a possible drug target for complicated pregnancies.

Authors:  Fergus P McCarthy; Aoife C Delany; Louise C Kenny; Sarah K Walsh
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

3.  15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway.

Authors:  Nirmal K Phulwani; Douglas L Feinstein; Vitaliy Gavrilyuk; Candan Akar; Tammy Kielian
Journal:  J Neurochem       Date:  2006-12       Impact factor: 5.372

4.  Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation.

Authors:  Peter Zahradka; Natalia Yurkova; Brenda Litchie; Michael C Moon; Dario F Del Rizzo; Carla G Taylor
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

5.  Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines.

Authors:  Samir S Ayoub; Regina M Botting; Amrish N Joshi; Michael P Seed; Paul R Colville-Nash
Journal:  Mol Cell Biochem       Date:  2009-02-15       Impact factor: 3.396

6.  The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.

Authors:  Wenpu Zhao; Seth G Thacker; Jeffrey B Hodgin; Hongyu Zhang; Jeffrey H Wang; James L Park; Ann Randolph; Emily C Somers; Subramaniam Pennathur; Matthias Kretzler; Frank C Brosius; Mariana J Kaplan
Journal:  J Immunol       Date:  2009-07-20       Impact factor: 5.422

7.  The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action.

Authors:  D M Kerr; B Harhen; B N Okine; L J Egan; D P Finn; M Roche
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 8.  Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.

Authors:  Maria G Belvisi; Jane A Mitchell
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

9.  Accumulation of 15-deoxy-delta(12,14)-prostaglandin J2 adduct formation with Keap1 over time: effects on potency for intracellular antioxidant defence induction.

Authors:  Joo Yeun Oh; Niroshini Giles; Aimee Landar; Victor Darley-Usmar
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

Review 10.  Regulation of obesity and insulin resistance by nitric oxide.

Authors:  Brian E Sansbury; Bradford G Hill
Journal:  Free Radic Biol Med       Date:  2014-05-28       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.